Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...
Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
Zacks.com on MSN2d
Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options
Investors in Regeneron Pharmaceuticals, Inc. REGN need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2025 $965 Call had some of the ...
Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...
Mena FN14d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report– Hagens Berman
SAN FRANCISCO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31 ...
Mena FN14d
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity To Lead Securities Fraud Lawsuit
The complaint filed alleges that, between November 2, 2023 and October 30, 2024, Defendants failed to disclose to investors: (1) that Regeneron paid credit card fees to distributors on the ...
Nasdaq14d
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report
With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...
Morningstar15d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
Insider Monkey16d
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. In one of his latest appearances on CNBC’s Squawk on the ...
Business Wire17d
Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the ...
Joplin Globe17d
Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...